IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	MITANI et al.	Examiner:	MUMMERT, Stephanie K.		
Serial No.:	10/583706	Group Art Unit:	1637		
Filed:	April 12, 2007	Docket:	20078.0001USWO		
Title:	: METHOD OF AMPLIFYING NUCLEIC ACID AND METHOD OF DETECTING MUTATED NUCLEIC ACID USING THE SAME				
	F TRANSMISSION at this paper is being transmitted by EFS Web to: Comrutober 12, 2010.		seron drope		
	INFORMATION DISCLOS	URE STATEMEN	<u>IT</u>		
Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450					
Sir:					
Action for C the Examine Action were	regard to the above-identified applic anadian Patent Application Number 2 r. Please note that the references cite previously cited in an Information D I cited by the Examiner on March 17,	2,504,234 is brough d in the enclosed C isclosure Statemen	at to the attention of canadian Office		
In accordance with the provisions of 37 C.F.R. §1.97, this statement is being filed (CHECK ONE):					
O:	within three (3) months of the Filing ffice Action on the merits, or before to the ction on the merits after the filing of ander 37 C.F.R. §1.114; or	he mailing date of	a First Office		
	after the period defined in (1) but bef ejection or Notice of Allowance, and	ore the mailing date	e of a Final		
⊠ the	e requisite Statement is below, OR				
th	e requisite fee of \$180.00 under Rule	1.17(p) is included	herein, or		
be	after the mailing date of a Final Rejection the payment of the Issue Fee, Al ND the requisite fee of \$180.00 unde	ND the requisite Sta	atement is below		

STATEMENT

	Applica	ants hereby state that				
		Statement was first in a counterpart app	lication or by the USPTO anths prior to the filing date	from a foreign patent office in a related application not		
	☐ If this box is checked, Applicant provides the following:					
Certification Under 37 C.F.R. §1.704(d)						
	In accordance with 37 C.F.R. §1.704(d), the undersigned hereby certifies that each item listed on the enclosed Form SB08 was first cited in a communication from a foreign patent office in a counterpart application, and that this communication was not received by any individual designated in 37 C.F.R. §1.56(c) more than thirty (30) days prior to the filing of this Information Disclosure Statement.					
The Examiner is hereby advised of the following co-pending U.S. applications. A copy of each U.S. patent application publication (if published) or application (if not published) is enclosed.						
	App	lication No.	Filing Date	Group		

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that a reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form SB08, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.

FEE AUTHORIZATION

Please charge any required fee or credit overpayment to Deposit Account No. 50-3478.

Respectfully submitted,

HAMRE, SCHUMANN, MUELLER &

LARSON, P.C. P.O. Box 2902

Minneapolis, MN 55402-0902

(612) 455-3800

Dated: 00 12 2010

Douglas P. Mueller Reg. No. 30,300

DPM:ji